Despite presenting longitudinal imaging and biological data from a prospective trial and providing a potential link between IL-6 and tumor hypoxia in HNSCC patients treated by chemoradiation, there are some limitations, especially the limited sample size and absent external validation. This evidence concerns the gene IL6 and neoplasm.